global glp-1 obesity drug market size forecast 2030 GLP-1 Agonists Market Report 2025-2033, By Product, Molecule, and Geo

Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss

25.85

★★★★☆4.0 (177)

Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. Adam

28.21

★★★★★4.5 (182)

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration's (FDA) “compassionate use program.” Read more:

26.45

★★★★★4.6 (202)

Retatrutide vs Tirzepatide: Key Differences for Researchers

23.89

★★★★★4.2 (147)

Reports claim that a single well-connected patient received early access to Eli Lilly's experimental weight-loss drug, Retatrutide, through the FDA's compassionate use program before approval. The patient was reportedly 79 years old,

28.95

★★★★★4.2 (220)

Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it's doing much more than what current medications can

23.89

★★★★★4.6 (202)

How to Get Retatrutide in 2026

28.93

★★★★★4.0 (28)